ROQUEFORT THERAPEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.45 GBX | 0.00% |
|
-2.20% | -38.62% |
| Apr. 26 | EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany | AN |
| Apr. 26 | Earnings Flash (ROQ.L) ROQUEFORT THERAPEUTICS Reports FY23 Loss GBX-1.35 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 637 810.04 | Sales 2022 | - | Capitalization | 8.56M 10.88M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 | Net income 2022 | -1M -1.27M | EV / Sales 2021 | 10,439 x |
| Net cash position 2021 | 900K 1.14M | Net cash position 2022 | 2.32M 2.95M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-3.77
x | P/E ratio 2022 |
-4.24
x | Employees | 9 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.02% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -2.20% | ||
| Current month | +1.14% | ||
| 1 month | -6.32% | ||
| 3 months | -42.58% | ||
| 6 months | -31.54% | ||
| Current year | -38.62% |
1 week
4.00
4.50
1 month
4.004.60
Current year
3.859.50
1 year
3.859.50
3 years
3.8513.63
5 years
3.8513.63
10 years
3.8513.63
| Managers | Title | Age | Since |
|---|---|---|---|
Ajan Reginald
CEO | Chief Executive Officer | 52 | 22-09-15 |
| Chairman | 51 | 20-08-16 | |
Armand Keating
CTO | Chief Tech/Sci/R&D Officer | - | 22-09-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jean Duvall
BRD | Director/Board Member | 63 | 22-04-04 |
Darrin Disley
BRD | Director/Board Member | 57 | 22-09-15 |
| Chairman | 51 | 20-08-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 4.45 | 0.00% | 0 |
| 24-05-20 | 4.45 | +2.30% | 318,202 |
| 24-05-17 | 4.35 | +2.35% | 107,337 |
| 24-05-16 | 4.25 | 0.00% | 337,571 |
| 24-05-15 | 4.25 | -6.59% | 120,022 |
Delayed Quote London S.E., May 21, 2024 at 02:59 am EDT
More quotes
Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Companyâs portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.
Calendar
2024-10-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -38.62% | 7.3M | |
| -0.81% | 120B | |
| +5.17% | 97.09B | |
| +13.89% | 68.89B | |
| +21.34% | 64.27B | |
| +13.26% | 44.08B | |
| +14.02% | 43.02B | |
| +23.44% | 36.47B | |
| +8.77% | 26.16B | |
| -0.40% | 23.24B |
- Stock Market
- Equities
- ROQ Stock
